Literature DB >> 11393680

Angiotensin converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of the isolated perfused rat heart.

L M de Lannoy1, M P Schuijt, P R Saxena, M A Schalekamp, A H Danser.   

Abstract

OBJECTIVES: Recent studies in homogenized hearts suggest that chymase rather than angiotensin converting enzyme (ACE) is responsible for cardiac angiotensin I to angiotensin II conversion. We investigated in intact rat hearts whether (i) enzymes other than ACE contribute to angiotensin I to angiotensin II conversion and (ii) the localization (endothelial/extra-endothelial) of converting enzymes. DESIGN AND METHODS: We used a modified version of the rat Langendorff heart, allowing separate collection of coronary effluent and interstitial fluid. Hearts were perfused with angiotensin I (arterial concentration 5-10 pmol/ml) under control conditions, in the presence of captopril (1 micromol/l) or after endothelium removal with 0.2% triton X-100. Endothelium removal was verified as the absence of a coronary vasodilator response to 10 nmol bradykinin. Angiotensin I and angiotensin II were measured in coronary effluent and interstitial fluid with sensitive radioimmunoassays.
RESULTS: In control hearts, 45% of arterial angiotensin I was metabolized during coronary passage, partly through conversion to angiotensin II. At steady-state, the angiotensin I concentration in interstitial fluid was three to four-fold lower than in coronary effluent, while the angiotensin II concentrations in both fluids were similar. Captopril and endothelium removal did not affect coronary angiotensin I extraction, but increased the interstitial fluid levels of angiotensin I two- and three-fold, respectively, thereby demonstrating that metabolism (by ACE) as well as the physical presence of the endothelium normally prevent arterial angiotensin I from reaching similar levels in coronary effluent and interstitial fluid. Captopril, but not endothelium removal, greatly reduced the angiotensin II levels in coronary effluent and interstitial fluid. With the ACE inhibitor, the angiotensin II/I ratios in coronary effluent and interstitial fluid were 83 and 93% lower, while after endothelium removal, the ratios were 33 and 71% lower.
CONCLUSIONS: In the intact rat heart, ACE is the main contributor to angiotensin I to angiotensin II conversion, both in the coronary vascular bed and the interstitium. Cardiac ACE is not limited to the coronary vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393680     DOI: 10.1097/00004872-200105000-00017

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Vasoconstriction is determined by interstitial rather than circulating angiotensin II.

Authors:  Martin P Schuijt; René de Vries; Pramod R Saxena; Maarten A D H Schalekamp; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Aliskiren: the first direct renin inhibitor for hypertension.

Authors:  Anton H van den Meiracker; A H Jan Danser
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 3.  Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system.

Authors:  Alicia C Reid; Jacqueline A Brazin; Christopher Morrey; Randi B Silver; Roberto Levi
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

4.  Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion.

Authors:  Christina J Mackins; Seiichiro Kano; Nahid Seyedi; Ulrich Schäfer; Alicia C Reid; Takuji Machida; Randi B Silver; Roberto Levi
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

5.  Mast cells: a unique source of renin.

Authors:  Randi B Silver; Alicia C Reid; Christina J Mackins; Trevor Askwith; Ulrich Schaefer; Doris Herzlinger; Roberto Levi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.